Humanwell Healthcare's subsidiary, Jushi Suan Changchun Ruibin Soft Capsule, has obtained the drug registration certificate.

Humanwell Healthcare (600079.SH) announced that its wholly-owned subsidiary, Wuhan Puke Pharmaceutical Co., Ltd. (referred to as "Wuhan Puke"), recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the oxaliplatin capecitabine soft capsules. It is reported that oxaliplatin capecitabine soft capsules have been approved for use in locally advanced or metastatic non-small cell lung cancer that is not amenable to surgical resection, as well as in metastatic breast cancer as monotherapy or in combination with chemotherapy. Wuhan Puke submitted the application for marketing approval of oxaliplatin capecitabine soft capsules to the National Medical Products Administration in October 2024 and has been accepted. As of now, the project has accumulated research and development investment of approximately 12 million RMB. According to Mynet data, the national sales of oxaliplatin capecitabine soft capsules are estimated to be around 860 million RMB in 2025, with the main manufacturers being PIERRE FABRE MEDICAMENT and Jiangsu Haosen Pharmaceutical Group Co., Ltd.